These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 12373862)

  • 1. [Paradoxical embolism in a case with Graves' ophthalmopathy during steroid therapy].
    Yonekura T; Ago T; Sato K; Okamura K; Fukuda K; Abe I; Iida M
    Nihon Naika Gakkai Zasshi; 2002 Aug; 91(8):2479-80. PubMed ID: 12373862
    [No Abstract]   [Full Text] [Related]  

  • 2. Venous occlusion does not release von Willebrand factor, factor VIII or PAI-1 from endothelial cells--the importance of consensus on the use of correction factors for haemoconcentration.
    Wieczorek I; Ludlam CA; MacGregor I
    Thromb Haemost; 1993 Jan; 69(1):91, 93. PubMed ID: 8446947
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].
    Brauer VF; Scholz GH
    Med Klin (Munich); 2004 Feb; 99(2):71-6. PubMed ID: 14963657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge.
    von Meijenfeldt FA; Havervall S; Adelmeijer J; Lundström A; Magnusson M; Mackman N; Thalin C; Lisman T
    Blood Adv; 2021 Feb; 5(3):756-759. PubMed ID: 33560386
    [No Abstract]   [Full Text] [Related]  

  • 5. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII:C and in erythrocyte sedimentation rate with age.
    Aillaud MF; Pignol F; Alessi MC; Harle JR; Escande M; Mongin M; Juhan-Vague I
    Thromb Haemost; 1986 Jun; 55(3):330-2. PubMed ID: 3092390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
    Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
    Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy of Four Treatments in Patients with Graves' Disease: a Network Meta-analysis.
    Ren Z; Qin L; Wang JQ; Li Y; Li J; Zhang RG
    Exp Clin Endocrinol Diabetes; 2015 May; 123(5):317-22. PubMed ID: 25988881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral parameters of oxidative stress in patients with infiltrative Graves' ophthalmopathy treated with corticosteroids.
    Bednarek J; Wysocki H; Sowiński J
    Immunol Lett; 2004 May; 93(2-3):227-32. PubMed ID: 15158621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serum Fas in patients with Graves' ophthalmopathy as a marker of activity of the ocular inflammatory infiltration].
    Myśliwiec J; Kretowski A; Stepień A; Okłota M; Kinalska I
    Pol Merkur Lekarski; 2004 Oct; 17(100):368-70. PubMed ID: 15690704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
    Molnár I
    Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose intravenous methylprednisolone therapy in patients with Graves' orbitopathy is associated with the increased activity of factor VIII.
    Miśkiewicz P; Milczarek-Banach J; Rutkowska-Hinc B; Kondracka A; Bednarczuk T
    J Endocrinol Invest; 2019 Feb; 42(2):217-225. PubMed ID: 29949121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graves' ophthalmopathy requires early steroid therapy.
    Freiwald MJ; González C
    Pa Med; 1986 Feb; 89(2):42, 44. PubMed ID: 3754321
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy.
    Wakelkamp IM; Prummel MF; Wiersinga WM
    Horm Metab Res; 2004 Jan; 36(1):44-7. PubMed ID: 14983406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The assessment of urinary glycosaminoglycans (GAG) excretion during therapy of patients with progressive Graves' ophthalmopathy].
    Pilarska K; Kulig G; Krzystolik Z
    Pol Arch Med Wewn; 2001 Feb; 105(2):139-44. PubMed ID: 11505748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
    Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial.
    Rautio A; Boman K; Gerstein HC; Hernestål-Boman J; Lee SF; Olofsson M; Mellbin LG
    Diab Vasc Dis Res; 2017 Jul; 14(4):345-352. PubMed ID: 28403644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graves' orbitopathy results in profound changes in tear composition: a study of plasminogen activator inhibitor-1 and seven cytokines.
    Ujhelyi B; Gogolak P; Erdei A; Nagy V; Balazs E; Rajnavolgyi E; Berta A; Nagy EV
    Thyroid; 2012 Apr; 22(4):407-14. PubMed ID: 22385289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum pro- and anti-inflammatory cytokines in patients with Graves' disease with ophthalmopathy during treatment with glucocorticoids.
    Myśliwiec J; Kretowski A; Szelachowska M; Mikita A; Kinalska I
    Rocz Akad Med Bialymst; 1999; 44():160-9. PubMed ID: 10697431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy.
    De Bellis A; Sansone D; Coronella C; Conte M; Iorio S; Perrino S; Battaglia M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
    Clin Endocrinol (Oxf); 2005 Jan; 62(1):24-9. PubMed ID: 15638866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The influence of hyperthyroidism and glucocorticosteroid treatment on bone metabolism in patients with Graves' disease and ophthalmopathy].
    Kaźmierczyk-Puchalska A; Kulig G; Krzyzanowska-Swiniarska B; Pilarska K
    Endokrynol Pol; 2005; 56(3):259-64. PubMed ID: 16350719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.